Details of the Drug

General Information of Drug (ID: DMU4ORS)

• Drug Name: Magnesium
• Synonyms: Magnesio; Magnesio [Italian]; Magnesium Matrix Modifier; Magnesium modifier; Magnesium powdered; Magnesium preparation; Magnesium sheet; LTBB002624; Magnesium hydride [UN2010] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; Magnesium nitrate-nitric acid solution; Rieke's active magnesium; MAGNESIUM, ATOMIZED POWDER,18MICRON; Magnesium granules, coated particle size not50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L;12Mg

Indication

Disease Entry	ICD 11	Status	REF
Ischemic stroke	8B11.5Z	Approved	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 24.305
  Topological Polar Surface Area; Not Available
  Rotatable Bond Count; 0
  Hydrogen Bond Donor Count; 0
  Hydrogen Bond Acceptor Count; 0
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 1000 hours [2]
  Metabolism: The drug is not metabolised [3]
  Vd: The volume of distribution (Vd) of drug is 13.65-49.00 L [4]
• Chemical Identifiers:
  Formula: Mg
  IUPAC Name: magnesium
  Canonical SMILES: [Mg]
  InChI: InChI=1S/Mg
  InChIKey: FYYHWMGAXLPEAU-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5462224
  ChEBI ID: CHEBI:25107
  CAS Number: 7439-95-4
  DrugBank ID: DB14513
  TTD ID: D0B8QB

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[1]

References

• [1] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [2] The Importance of Magnesium in Clinical Healthcare. Scientifica (Cairo). 2017;2017:4179326. doi: 10.1155/2017/4179326. Epub 2017 Sep 28.
• [3] Milosheska D, Lorber B, Vovk T, Kastelic M, Dolzan V, Grabnar I: Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016 Aug;82(2):399-411. doi: 10.1111/bcp.12984. Epub 2016 May 29.
• [4] Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, Duley L, Souza JP, Gulmezoglu AM: Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG. 2016 Feb;123(3):356-66. doi: 10.1111/1471-0528.13753. Epub 2015 Nov 24.
• [5] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [6] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [7] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [8] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [9] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [10] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [11] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [12] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [13] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [14] Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.